Management of Wide QRS Complex on ECG

Initial Assessment and Diagnosis

The American College of Cardiology recommends first determining if the patient is hemodynamically stable or unstable, with unstable patients requiring immediate DC cardioversion 1, 2, 3, 4
For patients with a wide QRS complex tachycardia, the American Heart Association suggests that stable vital signs do not help distinguish between SVT and VT 2
The American College of Cardiology states that a history of previous myocardial infarction strongly suggests VT, and first occurrence of wide QRS tachycardia after infarction also suggests VT 5, 6

The American College of Cardiology recommends considering AV dissociation with ventricular rate faster than atrial rate as a criterion for VT 2, 5
The American Heart Association suggests that a QRS width >0.14 seconds with RBBB pattern or >0.16 seconds with LBBB pattern is indicative of VT 2, 5
The American College of Cardiology states that an RS interval >100 ms in any precordial lead is a criterion for VT 5, 6

The American Heart Association recommends immediate DC cardioversion for hemodynamically unstable patients, regardless of the presumed mechanism 3, 4, 7
For hemodynamically stable patients, the American College of Cardiology suggests treating as VT if diagnosis is uncertain, and using IV procainamide and/or sotalol for pharmacologic termination of stable wide QRS-complex tachycardia of ventricular origin 3, 4, 2, 5
The American Heart Association recommends using amiodarone for patients with impaired LV function or heart failure, and lidocaine as second-line therapy 7

The American College of Cardiology states that pre-excited tachycardias and VT caused by digitalis toxicity require alternative approaches 3, 4
The American Heart Association suggests using adenosine for stable, regular, monomorphic wide-QRS tachycardia for both diagnosis and treatment, but not for unstable or irregular/polymorphic wide-complex tachycardia 7

The American College of Cardiology recommends referring patients to an arrhythmia specialist after successful termination of wide QRS-complex tachycardia of unknown etiology 3, 4
The American Heart Association suggests that patients with WPW syndrome should be referred for further evaluation, and that long-term management options include catheter ablation or drug therapy 3, 4

For unstable patients with wide QRS complex, the European Society of Cardiology recommends proceeding directly to synchronized DC cardioversion if tachycardia is present, due to the high risk of ventricular tachycardia 8, 9
The American College of Cardiology suggests that stable patients with wide QRS complex should undergo diagnostic evaluation and treatment of underlying causes, with a focus on correcting reversible causes such as electrolyte abnormalities and drug toxicity 8

The European Heart Rhythm Association recommends presuming ventricular tachycardia until proven otherwise in patients presenting with wide QRS complex tachycardia, due to the critical safety principle of avoiding calcium channel blockers in this setting 8, 9
The American Heart Association advises against using calcium channel blockers such as verapamil or diltiazem in wide-QRS tachycardia of unknown origin, as they can cause hemodynamic collapse if the rhythm is ventricular tachycardia 8, 9

The European Society of Cardiology recommends intravenous procainamide as a first-line pharmacologic option for stable monomorphic wide-QRS tachycardia, with a Class IIa recommendation 8
The American College of Cardiology suggests intravenous amiodarone as an alternative option for stable monomorphic wide-QRS tachycardia, with a Class IIa recommendation 8
The European Heart Rhythm Association recommends intravenous beta-blockers as a Class I recommendation for polymorphic VT, especially if ischemia is suspected 8, 9

The American College of Cardiology advises against using AV nodal blocking agents such as beta-blockers, calcium channel blockers, digoxin, or adenosine in patients with pre-excitation, as they can worsen the condition 10
The European Society of Cardiology recommends using procainamide or ibutilide for wide-QRS tachycardia with Wolff-Parkinson-White syndrome 10
The American Heart Association suggests using intravenous lidocaine for VT associated with acute myocardial infarction, with a Class IIb recommendation 8

Calcium‑channel blockers (verapamil, diltiazem) are absolutely contraindicated in wide‑complex tachycardia because they can precipitate hemodynamic collapse, ventricular fibrillation, and cardiac arrest when the rhythm is ventricular tachycardia (the most common cause of wide‑complex tachycardia). Class III (harm) recommendation. 11
These agents are potent negative inotropes that further depress already compromised ventricular contractility during ventricular tachycardia, increasing the risk of cardiovascular collapse. 12

The 2015 American Heart Association (AHA) Guidelines assign a Class III (contraindicated) recommendation to verapamil for wide‑complex tachycardias unless supraventricular origin is definitively proven. 11
The 2010 AHA Guidelines state unequivocally: “Verapamil should not be given to patients with wide‑complex tachycardias.” Class III. 12
Calcium‑channel blockers should be used only for narrow‑complex tachycardias (regular or irregular) where a supraventricular origin is certain. Class I (appropriate use). 13

Hemodynamic stability does not differentiate SVT from VT; patients with ventricular tachycardia may initially appear stable, creating a false sense of security. 14
The American Heart Association advises: “If the diagnosis of SVT cannot be proven or cannot be made easily, then the patient should be treated as if VT were present.” Class I recommendation. 14
Empiric use of calcium‑channel blockers for uncertain wide‑complex rhythms violates guideline recommendations and is associated with preventable mortality. Class III. 11

Drug	Recommended Class	Typical Indication
Procainamide	Class IIa (reasonable)	First‑line for stable monomorphic wide‑QRS tachycardia.
Amiodarone	Class IIb (may be considered)	Alternative, especially in patients with left‑ventricular dysfunction or heart failure.
Sotalol	Class IIb (may be considered)	Can be used unless the patient has a prolonged QT interval.

In Wolff‑Parkinson‑White syndrome with atrial fibrillation, AV‑nodal blockers (including calcium‑channel blockers, β‑blockers, digoxin, adenosine) can precipitate a dangerous acceleration of the ventricular rate by forcing conduction exclusively through the accessory pathway. Class III (harm). 12

Assume VT when SVT cannot be definitively proven; treat with procainamide or amiodarone—never with calcium‑channel blockers. Class III contraindication for CCBs. 11
Adenosine may be employed solely for diagnostic clarification in stable, regular, monomorphic wide‑complex tachycardia; it carries a Class IIb recommendation. 11
If the rhythm cannot be proven to be supraventricular, manage as VT per AHA guidance. Class I. 14